Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Loading
Home›
Research›
People›
Lynn Elliott
AddedMar 31, 2024
UpdatedMay 31, 2026
Lynn Elliott

Lynn Elliott

CEO, ShiraTronics

Crunchbase

Lynn Elliott's Career

ShiraTronics
ShiraTronics

Minneapolis, MN, US

CEO· C-Suite · Management
Avivomed
Avivomed

Minneapolis, MN, US

Co-Founder & CEO· C-Suite · Management

Create your profile now and gain access to exclusive deals and high-potential startups.

aVenture product preview
aVenture product preview
aVenture product preview

Lynn Elliott's Career

ShiraTronics
ShiraTronics
Series A$49.7M312018Minneapolis, MN, US
CEO· C-Suite · Management

Leadership at ShiraTronics

Mudit K JainMudit K JainBoard Member
Brad ValeBrad ValeBoard Member
Casey TanseyCasey TanseyBoard Member
Joyce EronyJoyce EronyBoard Member

Similar to ShiraTronics

AvivomedAvivomedMinneapolis, MN, USNeuromodulation Therapyest. 2021AvivomedMinneapolis, MN, US · est. 2021

Avivomed: Innovating neuromodulation tech for chronic disease treatment.

Series A · $32M13
RealeveRealeveMountain View, CA, USMedical Devicesest. 2007RealeveMountain View, CA, US · est. 2007

Realeve: Innovating miniaturized neurostimulation devices for advanced headache treatment.

Late Stage Private · $136.2M30
Scion NeurostimScion NeurostimDurham, NC, USMedical Devicesest. 2007Scion NeurostimDurham, NC, US · est. 2007

Scion Neurostim: Innovating non-invasive neurostimulation devices for migraine treatment since 2007.

Series A · $10M12
NociraNociraTempe, AZ, USMedical Devicesest. 2017NociraTempe, AZ, US · est. 2017

Nocira: A healthcare company specializing in migraine treatment devices.

Series B · $9.5M30
Avivomed
Avivomed
Series A$32M132021Minneapolis, MN, US
Co-Founder & CEO· C-Suite · Management

Leadership at Avivomed

Stephen MassonStephen MassonCo-Founder

Similar to Avivomed

Presidio MedicalPresidio MedicalSouth San Francisco, CA, USMedical Devicesest. 2017Presidio MedicalSouth San Francisco, CA, US · est. 2017

Presidio Medical: A medtech firm providing a neuromodulation platform for neuronal disorder remedies.

Series C · $102M59
Niche BiomedicalNiche BiomedicalLos Angeles, CA, USMedical Devicesest. 2016Niche BiomedicalLos Angeles, CA, US · est. 2016

Niche Biomedical: Innovating neuromodulation devices for enhanced human health.

Pre-Seed · $1.4M15
ShiraTronicsShiraTronicsMinneapolis, MN, USMedical Devicesest. 2018ShiraTronicsMinneapolis, MN, US · est. 2018

ShiraTronics: Innovating neuromodulation tech to transform lives affected by chronic migraines.

Series A · $49.7M31
Tal MedicalTal MedicalBoston, MA, USMedical Devicesest. 2011Tal MedicalBoston, MA, US · est. 2011

Tal Medical: Innovating non-contact neuromodulatory devices for psychiatric and neurological care.

Series A · $14.7M11

Lynn Elliott's Similar Executives & Operators

Achmad ZakyAchmad ZakyCo-Founder · BukalapakNugroho HerucahyonoNugroho HerucahyonoCo-Founder · BukalapakWillix HalimWillix HalimCEO · BukalapakWILL WEI CHENGWILL WEI CHENGCo-Founder · DiDiBo ZhangBo ZhangCo-Founder · DiDiDhirubhai H. AmbaniDhirubhai H. AmbaniFounder · Reliance RetailKim Beom-sooKim Beom-sooCo-Founder · KakaoBrian KimBrian KimCo-Founder · Kakao

People Similar to Lynn Elliott

Jim CorbettJim CorbettBoard Member · AVITA MedicalMike PerryMike PerryBoard Member · Avive SolutionsShengrong LinShengrong LinCo-Founder · AccuraGenLockett WoodLockett WoodCEO · Avivid Water TechnologyEric MillerEric MillerCo-Founder & CEO · Avi-on Labs